3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasms
1
Leukemia, Myeloid, Acute
1
Leukemia, Biphenotypic, Acute
1
Leukemia
1
BRAF V600E Mutation
1
Interventions
Cyclophosphamide
104
fludarabine
61
Methotrexate
50
Dexamethasone
47
Cytarabine
46
fludarabine phosphate
45
Vincristine
43
blinatumomab
36
Whole-Body Irradiation
33
Mycophenolic Acid
30
Tacrolimus
26
Melphalan
26
Mercaptopurine
25
venetoclax
24
Specimen Handling
24
Etoposide
24
pegaspargase
21
Peripheral Blood Stem Cell Transplantation
21
Stem Cell Transplantation
20
Granulocyte Colony-Stimulating Factor
19
Doxorubicin
19
Calcium Dobesilate
19
Busulfan
19
Rituximab
16
Prednisone
16
Filgrastim
16
Daunorubicin
16
Asparaginase
16
merphos
15
Thiotepa
15
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Precursor Cell Lymphoblastic Leukemia-Lymphoma
×
Cobicistat
×
1 year
×
Clear all
NCT04065399
2026-03-18
AUGMENT-101
Syndax Pharmaceuticals
Phase 1/2
Recruiting
447 enrolled
2 FDA